ProMark: An 8-Protein Signature

Protein levels provide more direct reflection of diseased state. mRNA levels do not always lead to changes in protein expression.
Unlike genomic based tests that require pathologist to indicate the areas of tumors, ProMark technology allows for analysis of proteins directly from the cancerous regions of interest in an objective and automated approach.
Tumor specificity measurement of ProMark is 99.9%.

ProMark was developed with eight carefully selected biomarkers which are resistant to sampling variability and pathologist discordance, and exhibit performance for both disease aggressiveness and lethal outcome.

ProMark’s quantitative immunofluorescence method utilizes state-of-the-art imaging technology to measure these eight biomarkers directly on sections of biopsy tissue.

Learn more about how ProMark works.

DERL1 (in both tumor and benign)	A protein involved in endoplasmic reticulum degradation of misfolded lumen proteins
CUL2 (in both tumor and benign)	A bundling protein that anchors actin to a variety of intracellular structures
SMAD4	A component of the Transforming Growth Factor-β signaling pathway, involved in the regulation of cell proliferation, apoptosis, and differentiation
PDSS2	An enzyme that synthesizes the phenyl side-chain of coenzyme Q, a key element in the respiratory chain
HSPA9	A member of the heat shock protein 70 family involved in cell proliferation, stress response, and the maintenance of the mitochondria
FUS	A component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex involved in pre-mRNA splicing and the export of fully processed RNA into the cytoplasm
pS6 (phosphorylated S6)	A component of the 40s ribosome subunit involved in protein synthesis; its phosphorylation reflects the PI3K and core MAPK pathway signaling activity
YBOX1	A cytoplasmic mRNA-binding protein involved in pre-mRNA alternative splicing